Azithromycin — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Bacterial Infections

• Amoxicillin
• Ciprofloxacin
• Doxycycline
• Levofloxacin
• Metronidazole

Other medications in Infectious Disease

• Bictegravir/Emtricitabine/TAF
• Dolutegravir/Lamivudine
• Elbasvir/Grazoprevir
• Emtricitabine/Tenofovir
• Glecaprevir/Pibrentasvir
• Molnupiravir
• Nirmatrelvir/Ritonavir
• Nitrofurantoin

About Azithromycin

Azithromycin is a widely prescribed antibiotic, essential for treating various bacterial infections from respiratory issues to skin conditions. At TheDrugClub, we believe vital medications like azithromycin should be accessible and affordable.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Azithromycin is approved for (FDA label)

Azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below.

Source: Read the full FDA label on DailyMed. Label effective date: September 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Azithromycin (FDA label)

Azithromycin Tablets USP, 250 mg are white to off-white, modified capsule shaped, film-coated biconvex tablets, debossed with “66” on one side and “D” on other side. These are packaged in bottles and blister packs. Azithromycin Tablets USP, 500 mg are white to off-white, oval shaped, film-coated biconvex tablets, debossed with “67” on one side and “D” on other side. These are packaged in bottles and blister packs. Azithromycin tablets USP 250 mg and 500 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 94e17ae5-0871-67a0-e053-2995a90ae0ae. SPL document ID: 5b15aee0-ff94-23be-e063-6394a90a963e. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Azithromycin (FDA label)

Most common adverse reactions are diarrhea (5 to 14%), nausea (3 to 18%), abdominal pain (3 to 7%), or vomiting (2 to 7%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, most of the reported side effects were mild to moderate in severity and were reversible upon discontinuation of the drug.

Source: FDA prescribing information (DailyMed). Set ID: 94e17ae5-0871-67a0-e053-2995a90ae0ae. SPL document ID: 5b15aee0-ff94-23be-e063-6394a90a963e. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Azithromycin (FDA label)

Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug. ( 4.1 ) Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. ( 4.2 ) 4.1 Hypersensitivity Azithromycin tablets are contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drug. 4.2 Hepatic Dysfunction Azithromycin tablets are contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin.

Source: FDA prescribing information (DailyMed). Set ID: 94e17ae5-0871-67a0-e053-2995a90ae0ae. SPL document ID: 5b15aee0-ff94-23be-e063-6394a90a963e. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Azithromycin (FDA label)

Serious (including fatal) allergic and skin reactions: Discontinue azithromycin if reaction occurs. ( 5.1 ) Hepatotoxicity: Severe, and sometimes fatal, hepatotoxicity has been reported. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur. ( 5.2 ) Infantile Hypertrophic Pyloric Stenosis (IHPS): Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs. ( 5.3 ) Prolongation of QT interval and cases of torsades de pointes have been reported.

Source: FDA prescribing information (DailyMed). Set ID: 94e17ae5-0871-67a0-e053-2995a90ae0ae. SPL document ID: 5b15aee0-ff94-23be-e063-6394a90a963e. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Azithromycin (FDA label)

Nelfinavir: Close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. ( 7.1 ) Warfarin: Use with azithromycin may increase coagulation times; monitor prothrombin time. ( 7.2 ) 7.1 Nelfinavir Co-administration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. [see Adverse Reactions (6) ] 7.2 Warfarin Spontaneous postmarketing reports suggest that concomitant administration of azithromycin may potentiate the effects of oral anticoagulants such as warfarin, although the prothrombin time was not affected in the dedicated drug interaction study with azithromycin and warfarin.

Source: FDA prescribing information (DailyMed). Set ID: 94e17ae5-0871-67a0-e053-2995a90ae0ae. SPL document ID: 5b15aee0-ff94-23be-e063-6394a90a963e. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.